D-6-thio-glucose | 13406-56-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-6-thio-glucose
• 英文别名: 6-Thio-D-glucose；D-gluco-2,3,4,5-Tetrahydroxy-6-mercapto-hexanal；D-Glucose, 6-thio-；(2R,3S,4S,5S)-2,3,4,5-tetrahydroxy-6-sulfanylhexanal
• CAS: 13406-56-9
• 化学式: C₆H₁₂O₅S
• 分子量: 196.224
• InChiKey: CMAPKTMUFOTYAF-SLPGGIOYSA-N

物化性质

• 沸点：
  457.0±45.0 °C(Predicted)
• 密度：
  1.503±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  99
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  D-6-thio-glucose 、 乙酸酐 在 吡啶 作用下， 生成 1,2,3,4-tetra-O-acetyl-6-S-acetyl-6-thio-β-D-glucopyranose
  参考文献：
  名称：

  Ohle; Mertens, Chemische Berichte, 1935, vol. 68, p. 2176,2186

  摘要：

  DOI：
• 作为产物：
  描述：

  5,6-anhydro-1,2-O-isopropylidene-α-D-glucofuranose 在 barium dihydroxide 、 硫酸 、 硫化氢 、 水 作用下， 生成 D-6-thio-glucose
  参考文献：
  名称：

  Ohle; Mertens, Chemische Berichte, 1935, vol. 68, p. 2176,2186

  摘要：

  DOI：

文献信息

• Fatty acid metabolism inhibitors for use in the treatment of cancer
  申请人：The Board of Regents of the University of Colorado

  公开号：EP2377528A2

  公开（公告）日：2011-10-19

  A composition for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. The composition can be used to treat drug-resistant or multi-drug resistant cancers.

  一种用于治疗炎症和增生性疾病以及伤口的组合物，以脂肪酸代谢抑制剂为药剂，可选择与一种或多种化疗药物结合使用。该组合物可用于治疗耐药性或多重耐药性癌症。
• Clip inhibitors and methods of modulating immune function
  申请人：The Regents of the University of Colorado

  公开号：EP2633864A1

  公开（公告）日：2013-09-04

  The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, allergic disease transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS.

  本发明涉及通过靶向 CLIP 分子调节免疫功能的方法。其结果是产生了多种新的治疗方案，用于治疗、抑制发展或以其他方式处理多种疾病和病症，包括自身免疫性疾病、过敏性疾病、移植和细胞移植物排斥、癌症、细菌感染、艾滋病病毒感染和艾滋病。
• Reprogramming of cells to a new fate
  申请人：The Scripps Research Institute

  公开号：US10308912B2

  公开（公告）日：2019-06-04

  The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.

  本发明一般提供动物细胞从第一种非全能细胞命运向第二种非全能细胞命运转分化的方法和组合物。本发明还提供了将动物细胞从非多能中胚层、内胚层或外胚层细胞命运转分化为不同的非多能中胚层、内胚层或外胚层细胞命运的方法和组合物。
• Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
  申请人：Propanc Pty Ltd

  公开号：US10350239B2

  公开（公告）日：2019-07-16

  The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumor cell to enhance cell-to-cell adhesion of tumor cells, effect proteolysis of tumor cells, or induce tumor cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumor cells.

  本发明一般涉及含有蛋白酶原的药物组合物及其治疗癌症的用途。这些药物组合物涉及包含蛋白酶原和活性剂的组合物，该组合物能够提供治疗癌症的多功能方法。本发明的药物组合物还涉及包含第一和第二蛋白酶原的组合物，第一和第二蛋白酶原能够在肿瘤细胞表面或其附近活化，以增强肿瘤细胞的细胞间粘附性，影响肿瘤细胞的蛋白分解，或诱导肿瘤细胞凋亡、分化或免疫认知，其中第一蛋白酶原是糜蛋白酶原，第二蛋白酶原是胰蛋白酶原。该药物组合物还涉及包含第一和第二活性剂的组合物，每种活性剂都能诱导肿瘤细胞的细胞内活性。
• Competitive inhibitors of invariant chain expression and/or ectopic clip binding
  申请人：Regents of the University of Colorado, a body corporate

  公开号：US10420813B2

  公开（公告）日：2019-09-24

  The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.

  本发明涉及通过靶向 CLIP 分子调节免疫功能的方法。其结果是提供了广泛的新的治疗方案，用于治疗、抑制发展或以其他方式处理多种疾病和病症，包括自身免疫性疾病、癌症、老年痴呆症、过敏性疾病、移植和细胞移植物排斥反应、艾滋病病毒感染和其他病毒、细菌和寄生虫感染以及艾滋病。还提供了制备具有能够置换 CLIP 特性的多肽的方法，方法是将一个或多个多肽序列输入预测抗原序列中 MHC II 类结合区域的软件及相关产品中。